checkAd
    Startseite > Aktien > Acticor Biotech > Nachrichten
    Acticor Biotech Aktie
    0,9360
     
    EUR
    -3,51 %
    -0,0340 EUR
    Letzter Kurs 17.05.24 Frankfurt
    0,8900
     
    EUR
    2.248 STK
    Geldkurs 17.05.24
    1,0350
     
    EUR
    1.933 STK
    Briefkurs 17.05.24
    ISIN: FR0014005OJ5 · WKN: A3C6GM · SYM: 7V7 · Frankreich

    Neueste Nachrichten

    ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
    15.05.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023
    30.04.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment
    25.04.24 · Business Wire (engl.) · Acticor Biotech
    Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
    15.04.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of March 31, 2024
    05.04.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of February 29, 2024
    18.03.24 · Business Wire (engl.) · Acticor Biotech
    Acticor Biotech Completes a Capital Increase for a Total Gross Amount of 8 Million Euros
    15.03.24 · Business Wire (engl.) · Acticor Biotech
    Acticor Biotech Launches a Capital Increase of a Minimum of 7 Million Euros
    14.03.24 · Business Wire (engl.) · Acticor Biotech
    The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attacks
    07.02.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2024
    06.02.24 · Business Wire (engl.) · Acticor Biotech
    Acticor Biotech Announces Its Financial Calendar for the 1st Half of 2024
    25.01.24 · Business Wire (engl.) · Acticor Biotech
    ACTICOR BIOTECH: Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal
    23.01.24 · Business Wire (engl.) · Acticor Biotech